<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342325</url>
  </required_header>
  <id_info>
    <org_study_id>CAMCR013</org_study_id>
    <secondary_id>jRCT2043200002</secondary_id>
    <nct_id>NCT04342325</nct_id>
  </id_info>
  <brief_title>The Clinical Trial of ADR-001 for IgA Nephropathy</brief_title>
  <official_title>Open-label, Multiple-center, Dose-Escalation Study to Evaluate the Safety and Tolerability of ADR-001 for the Treatment for Immunoglobulin A (IgA) Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rohto Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nagoya University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in
      Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the
      efficacy of ADR-001 for IgA Nephropathy patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>3 + 3 dose escalation study design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>until 6 weeks after first administration</time_frame>
    <description>Any adverse events are summarized.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical remission (proteinuria, hematuria)</measure>
    <time_frame>at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration</time_frame>
    <description>Ratio and time frame to achieve remission are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration</time_frame>
    <description>Change from baseline value and ratio to achieve threshold are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematuria</measure>
    <time_frame>at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration</time_frame>
    <description>Change from baseline value and ratio to achieve threshold are summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>at 2, 4, 6, 12, 26, 38 and 52 weeks after first administration</time_frame>
    <description>Change from baseline value are summarized.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Glomerulonephritis , IGA</condition>
  <arm_group>
    <arm_group_label>ADR-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of ADR-001 (Mesenchymal stem cell)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infusion of ADR-001 (Mesenchymal stem cell)</intervention_name>
    <description>Once or twice with two week interval at a dose of 100 x 10 ^ 6 cells.</description>
    <arm_group_label>ADR-001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. IgA nephropathy diagnosed by renal biopsy.

          2. Meet any of the following criteria.

             i. Urinary protein at screening is 0.5 g / gCr or more and eGFR is 60 mL / min /
             1.73m^2 or more even if corticosteroids are used for 6 months or more before
             screening.

             ii. Urine protein of 1.0 g / gCr or more and eGFR of 30 mL / min / 1.73 m^2 or more
             and less than 60 mL / min / 1.73 m^2 at screening even if corticosteroids are used for
             6 months or more before screening.

             iii. Urine protein of 0.5 g / gCr or more and less than 1.0 g / gCr at screening and
             eGFR of 20 mL / min / 1.73m^2 or more and 60 mL / min / 1.73m^2 or urine protein of
             1.0 g / gCr or more at screening And eGFR is 20 mL / min / 1.73m^2 or more and less
             than 30 mL / min / 1.73m^2.

          3. Over 20 years old.

          4. Able to provide informed consent.

        However, in the first cohort, only 2) -i is applied in the selection criteria 2), and in
        the second cohort, 2) -i, ii, and iii are applied.

        Exclusion Criteria:

          1. Nephropathy other than IgA nephropathy, and primary and secondary nephrotic syndrome.

          2. Start or increase drug therapy for IgA nephropathy with corticosteroids,
             immunosuppressants, renin angiotensin system (RAS ) inhibitors, antiplatelet drugs,
             anticoagulants (warfarin), and n-3 fatty acids (fish oil) within 3 months . Palatal
             tonsillectomy within 6 months.

          3. Treatment with other cells.

          4. Participated within 3 months or participating in other clinical trials .

          5. Penal transplantation within 3 years or scheduled.

          6. Diabetics not well controlled.

          7. Malignant neoplasm or history of malignant neoplasm within 5 years, or judged
             possibility of malignant tumor.

          8. Suspected of active infection.

          9. Positive for hepatitis B (HB), hepatitis C virus (HCV),human Immunodeficiency virus
             (HIV), human T-cell leukemia virus 1 (HTLV-1) or syphilis.

         10. History of severe hypersensitivity or anaphylactic reaction.

         11. Allergic to penicillin antibiotics, aminoglycoside antibiotics or dimethyl sulfoxide
             (DMSO).

         12. Serious complications not related to IgA nephropathy.

         13. Bleeding or may bleed, shallow days after surgery or trauma to the central nervous
             system, history of hypersensitivity to components of heparin preparations, history of
             heparin-induced thrombocytopenia Previous patient.

         14. During pregnancy, lactation, may be pregnant or both men and women who do not agree to
             give birth control under the guidance of the investigator or investigator during the
             study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shoichi Maruyama, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Nagoya University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shoichi Maruyama, MD, PhD</last_name>
    <phone>+81-52-744-2192</phone>
    <email>marus@med.nagoya-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kazuhiro Furuhashi, MD, PhD</last_name>
    <phone>+81-52-744-2192</phone>
    <email>furu13@med.nagoya-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasugai Municipal Hospital</name>
      <address>
        <city>Kasugai</city>
        <state>Aichi</state>
        <zip>486-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yosuke Saka, MD, PhD</last_name>
      <phone>+81-568-57-0057</phone>
      <email>yosukesaka@hospital.kasugai.aichi.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>566-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shoichi Maruyama, MD, PhD</last_name>
      <phone>+81-52-744-2192</phone>
      <email>marus@med.nagoya-u.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Kazuhiro Furuhashi, MD, PhD</last_name>
      <phone>+81-52-744-2192</phone>
      <email>furu13@med.nagoya-u.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nagoya University</investigator_affiliation>
    <investigator_full_name>Shoichi Maruyama MD PhD</investigator_full_name>
    <investigator_title>Professor at Department of Nephrogy, Graduate school of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

